Aripiprazole Tablet
Product Images NDC 0904-7367

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 0904-7367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Aripiprazole Tablets 1)

Chemical structure of Aripiprazole, showing its molecular framework including a dichlorophenyl group, a piperazine ring, and a quinolinone moiety, connected by an ether-linked chain.*

FDA Label Image

1 (Aripiprazole Tablets 10)

Line chart showing change in YGTSS Total TIC Score from baseline over 8 weeks of treatment, comparing Aripiprazole low dose, Aripiprazole high dose, and placebo. The y-axis represents the least-squares mean change in YGTSS Total TIC Score, and the x-axis represents weeks of treatment. The chart illustrates a greater reduction in score with both doses of Aripiprazole compared to placebo over time.*

FDA Label Image

1 (Aripiprazole Tablets 2)

A pharmacokinetic chart showing the effect of various drugs on aripiprazole. It illustrates fold changes and 90% confidence intervals for aripiprazole's AUC and Cmax values when co-administered with CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs. The x-axis represents change relative to reference without interacting drugs.*

FDA Label Image

1 (Aripiprazole Tablets 3)

A pharmacokinetic chart titled "Effect of Other Drugs on Aripiprazole" showing dehydro-aripiprazole fold change with 90% confidence intervals. The chart compares the impact of various inhibitors, inducers, and other drugs on Aripiprazole AUC and Cmax relative to a reference without interacting drugs, with values ranging from about 0.5 to 3.0 fold change.*

FDA Label Image

1 (Aripiprazole Tablets 4)

A forest plot chart illustrating the effect of Aripiprazole on the pharmacokinetics of various drugs, including CYP2D6 substrates (dextromethorphan), CYP2C9 and CYP2C19 substrates (warfarin), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents change relative to reference values without interacting drugs, with fold change and 90% confidence intervals shown for each drug. The plot assesses changes in drug exposure parameters such as AUC and Cmax.*

FDA Label Image

1 (Aripiprazole Tablets 5)

A pharmacokinetic chart illustrating the fold change and 90% confidence interval in aripiprazole exposure (AUC and Cmax) across special populations, including comparisons for CYP2D6 poor versus extensive metabolizers, gender, age groups (18-64 vs. >65 years), levels of hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment. The x-axis represents change relative to reference values.*

FDA Label Image

1 (Aripiprazole Tablets 6)

A pharmacokinetic chart showing the fold change and 90% confidence interval of Dehydro-Aripiprazole relative to reference across various factors: CYP2D6 metabolic status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis measures change relative to reference, and the y-axis lists the factors with corresponding AUC and Cmax values.*

FDA Label Image

1 (Aripiprazole Tablets 7)

A Kaplan-Meier curve comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk is listed below the graph for both groups.*

FDA Label Image

1 (Aripiprazole Tablets 8)

A Kaplan-Meier survival curve chart comparing the proportion with relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk at different time points for both groups.*

FDA Label Image

1 (Aripiprazole Tablets 9)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis represents days, with numbers of subjects at risk below, and the y-axis shows the proportion with relapse. The graph includes a legend differentiating Aripiprazole (solid line) and placebo (dashed line).*

FDA Label Image

Carton Label 2 mg (Image 01)

Packaging label for Aripiprazole 2 mg tablets, USP, by Major Pharmaceuticals. The label indicates a unit dose form containing 30 tablets (3 blister cards of 10 tablets each). It specifies pharmacist dispensing with a medication guide and notes storage instructions and safety warnings. The label includes NDC 0904-7366-04 and is marked for prescription use only.*

FDA Label Image

Carton Label 5 mg (Image 02)

Aripiprazole 5 mg tablets unit dose packaging label from Major Pharmaceuticals. The label displays the product name, strength, quantity of 100 tablets (10 x 10), and directions for storage and use. It indicates the product is prescription only and includes the NDC number 0904-7367-61 along with labeling for pharmacist dispensing with a medication guide.*

FDA Label Image

Carton Label 10 mg (Image 03)

Packaging label for Aripiprazole 10 mg oral tablets, Unit Dose format, from Major Pharmaceuticals. The label indicates 100 tablets (10 x 10) with instructions for pharmacists to dispense with Medication Guide. It includes storage information, a warning that this unit dose package is not child-resistant and intended for institutional use only, and a barcode with NDC 0904-7368-61.*

FDA Label Image

Carton Label 15 mg (Image 04)

Aripiprazole Tablets USP 15 mg oral unit dose packaging label by Major Pharmaceuticals. The label indicates a package of 30 tablets (3 blister packs of 10 tablets each) with directions to dispense with a medication guide. The label includes storage instructions, a note that the unit dose package is not child-resistant, and mentions the product is Rx only.*

FDA Label Image

Carton Label 20 mg (Image 05)

Aripiprazole 20 mg tablets USP unit dose packaging label from Major Pharmaceuticals, containing 30 tablets (3 blister packs of 10). The label includes storage instructions, dosage warnings, and pharmacy dispensing guidance, specifying Rx only. It features the NDC 0904-7370-04 and states the product is for institutional use only.*

FDA Label Image

Carton Label 30 mg (Image 06)

Aripiprazole 30 mg oral tablets unit dose packaging label from Major Pharmaceuticals. The label indicates 30 tablets (3 x 10) with instruction to dispense with a medication guide. Storage conditions and regulatory information are provided, along with Major Pharmaceuticals contact details in Indianapolis, IN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.